Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
Novo Nordisk’s Strategic Acquisition of Catalent: Short-term Challenges but Long-term Growth Potential with a Buy Recommendation
TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...
Novo Nordisk Unusual Options Activity
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Novo Nordisk: Excellent Opportunity To Buy The Dip
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
Argus Research Remains a Buy on Novo Nordisk (NVO)
In a report released yesterday, Jasper Hellweg from Argus Research maintained a Buy rating on Novo Nordisk (NVO – Research Report). The ...
Novo Nordisk A/S - share repurchase programme
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...
devdiscourse1d
Denmark's Diplomatic Push: Navigating Greenland Tensions
Denmark's Prime Minister Mette Frederiksen initiated discussions with business leaders in response to U.S. President-elect ...
Novo Nordisk, other companies meet Danish prime minister following Trump's Greenland threat
The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's Prime Minister ...
Biden adds weight loss drugs to Medicare price negotiations
Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.